Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle® Treatment Following Switch From Trisekvens®

This study is conducted in Europe. The aim of this study is to investigate the bleeding profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)).

Inclusion Criteria:

• Healthy women
• At least 3 months on Trisekvens® before screening period
• Ability to understand and comply with the protocol requirements

Exclusion Criteria:

• Less than 12 months or more than 36 months postmenopausal judged by the Investigator
• Known, suspected, or past history of hormone dependent tumor/cancers
• Deep venous thrombosis, active thrombophlebitis, thromboembolic disorders, cerebrovascular accidents or past history of these conditions
• Ischemic heart disease or myocardial infarction within 6 months prior to randomization